Showing results (421-430 of 513) with videos related to

Sort By:
Pageof 52
Breast Cancer Research and Treatment|September 13, 2008
Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapyBhumsuk Keam, Seock-Ah Im, Hee-Jun Kim, et al.
International Journal of Radiation Oncology, Biology, Physics|July 27, 2022
Association of T Cell Senescence with Radiation Pneumonitis in Patients with Non-small Cell Lung CancerKyung Hwan Kim, Hongryull Pyo, Hoyoung Lee, et al.
Targeted Oncology|October 24, 2023
A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaAlbiruni R Abdul Razak, Hung-Ming Wang, Jang-Yang Chang, et al.
The Journal of Pathology|July 26, 2017
Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancerKa-Won Noh, Mi-Sook Lee, Seung Eun Lee, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 13, 2023
Whole-Section Landscape Analysis of Molecular Subtypes in Curatively Resected Small Cell Lung Cancer: Clinicopathologic Features and Prognostic SignificanceSoohyun Hwang, Tae Hee Hong, Hong Kwan Kim, et al.
BMC Cancer|September 14, 2017
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancerKerry Lynn Reynolds, Philippe L Bedard, Se-Hoon Lee, et al.
Cancer Research and Treatment|April 7, 2010
Esophageal squamous cell carcinoma recurring as a solitary renal massDo Hyoung Lim, Young-Hyuck Im, Sang Hoon Ji, et al.
Lung Cancer (Amsterdam, Netherlands)|March 14, 2025
A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancerByoung Chul Cho, Melissa Johnson, Jair Bar, et al.
European Journal of Cancer (Oxford, England : 1990)|July 19, 2024
Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLCMaximilian J Hochmair, Karim Vermaelen, Giannis Mountzios, et al.
Lancet (London, England)|September 17, 2024
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trialJonathan D Spicer, Marina C Garassino, Heather Wakelee, et al.
Pageof 52